Sign in to view content

Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen

Michael J Allingham, MD, PhD

Video
Published 2019

Michael J. Allingham, MD, PhD

AMD Non-neovscular Symposium

Related

Clinical Effects of Blocking Ang-2 and VEGF with Faricimab in the Phase 2 STAIRWAY Trial
Carl J Danzig, MD
Annual Meeting Talks
2020
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
Real-World Evidence for Pneumatic Retinopexy in Patients With Primary Rhegmatogenous Retinal Detachment Meeting PIVOT Trial Criteria
Verena Juncal, MD
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more